Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714863 | 1.00 | FFAR4 (0.49) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL17391191 | 0.89 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL29188003 | 0.89 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL29018749 | 0.89 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL5447182 | 0.89 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL5924916 | 0.89 | FFAR4 (0.57) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL19714832 | 0.86 | CPB1 (0.46) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL19730184 | 0.86 | CPB1 (0.46) | FFAR4AGTR2ALDH1A1CYP1A2TSHR | |
| SCHEMBL19730186 | 0.82 | TSHR (0.42) | FFAR4AGTR2TSHRLMNAACHE | |
| SCHEMBL6409645 | 0.81 | FFAR4 (0.62) | FFAR4AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | FFAR4 1608/4885AGTR2 180/4885ALDH1A1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.